Please use this identifier to cite or link to this item:
|Title:||Achieving the deep molecular response levels required for an imatinib discontinuation trial is strongly associated with the BCR-ABL level at the first qualifying timepoint|
|Citation:||Abstract of power point presentation at 56th ASH Annual Meeting, published in Blood, 2014 / vol.124, iss.21, pp.4561|
|Publisher:||American Society of Hematology|
|Conference Name:||56th ASH Annual Meeting (06 Dec 2014 - 09 Dec 2014 : San Francisco, California)|
|Susan Branford, David M Ross, David T Yeung, Jodi Braley, and Timothy P. Hughes|
|Rights:||© 2014 by The American Society of Hematology|
|Appears in Collections:||Medicine publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.